← SynDRA
CYCLOSERINE
SynDRA canonical compound SYN0001772 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | GRIN1 |
| Mechanism of action | bacterial cell wall synthesis inhibitor |
| Indication | tuberculosis |
| Disease area | infectious disease |
All known targets
- GRIN1
- CYP3A4
- Grin2b
- alr
- MycB ddl
- MycB alr
- Grin3b
- Grin3a
- Grin2d
- Grin2c
- Grin2a
- Grin1
Mechanisms of action (all sources)
- bacterial cell wall synthesis inhibitor
- MycB ddl INHIBITOR
- MycB alr INHIBITOR
- GRIN1 INHIBITOR
- ddl INHIBITOR
- alr INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- ADORA3
- KCNH2
- KDR
- LMNA
- MAOA
- MAPK1
- MPHOSPH8
- OPRM1
- PDE3A
- PDE4A
- PGR
- PTGS1
- RGS4
- SAMHD1
- SLC6A2
- SLC6A3
- SLC6A4
- SMN1
- TBXA2R
- TDP1
- HTR2B
- HTR1A
- HSD17B10
- CYP2C19
- ADRA1A
- ADRA2A
- AR
- BLM
- CBX1
- CHRM1
- CHRM2
- CYP1A2
- CYP2C9
- HRH3
- CYP2D6
- DRD1
- DRD3
- EHMT2
- ESR1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Anti-Bacterial Agents
- Anti-Infective Agents
- Anti-Infective Agents, Urinary
- Antibiotics, Antitubercular
- Antimetabolites
- Antitubercular Agents
- Noxae
ATC classes
- J04A · DRUGS FOR TREATMENT OF TUBERCULOSIS
Cross-references
Synonyms
- SEROMYCIN
- Seromycin
- seromycin
- oxamycin
- farmiserina
- miroseryn
- cyclorin
- Cicloserina
- Cycloserinum
- D-cycloserine
- Orientomycin
- NSC-154851
- NSC-76029
- orientomycin
- Oxamycin
- Cyclorin
- Cyclo-D-serine
- Wasserina
- Farmiserina
- Tisomycin
- Miroseryn
- Closina
- D-4-amino-3-isoxazolidinone
- alpha-Cycloserine
- (+)-4-Amino-3-isoxazolidinone
- Miroserina
- D-4-amino-3-isoxazolidone
- Oxamicina
- PA-94
- (+)-Cycloserine
- Oxamicina [Italian]
- Cycloserin
- Micoserina
- Cicloserina [Italian]
- Tebemicina
- Novoserin
- D-Oxamycin
- Closerin
Reported adverse events
- Aggression
- Coma
- Dysarthria
- Headache
- Hyperreflexia
- Paresis
- Tremor
- Vertigo
Look up CYCLOSERINE in the interactive SynDRA portal →